<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01181999</url>
  </required_header>
  <id_info>
    <org_study_id>ML25393</org_study_id>
    <nct_id>NCT01181999</nct_id>
  </id_info>
  <brief_title>Rituximab Augmentation Following R-CHOP Induction Chemotherapy in Extremely Elderly Patients With Diffuse Large B Cell Lymphoma</brief_title>
  <official_title>Phase II Trial of Rituximab (R) Augmentation Following R-CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone) Induction Chemotherapy in Extremely Elderly Patients With Diffuse Large B Cell Lymphoma (DLBCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chonnam National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rituximab (R) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone)
      combination is considered as the new gold standard for the first-line treatment of elderly
      patients with diffuse large B-cell lymphoma (DLBCL).

      The study is aimed to evaluate the overall response rate and the safety of four cycles of
      R-CHOP chemotherapy and followed by rituximab augmentation (weekly four times infusion) in
      newly diagnosed DLBCL patients with aged more than 70 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Four cycles of R-CHOP chemotherapy for the induction treatment [Dose intensity of CHOP
           chemotherapy is modulated according to Charlson Comorbidity Index (CCI)]

           If patients with CCI &lt;1

             -  Rituximab: 375 mg/m2, day 1 every 3 weeks.

             -  Conventional dose of CHOP chemotherapy repeat every 3 weeks.

           If patients with CCI ≥1

             -  Rituximab: 375 mg/m2, day 1 every 3 weeks.

             -  75% of conventional CHOP repeat every 3 weeks.

        2. Rituximab augmentation

             -  Rituximab: 375 mg/m2, every week x 4 times.

             -  Trimethoprim-sulfamethoxazole 1 tablet per day during augmentation
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the overall response rate</measure>
    <time_frame>three years after the completion of rituximab augmentation</time_frame>
    <description>To evaluate the objective overall response rate of four cycles of R-CHOP and followed by four times weekly rituximab augmentation in exteremely elderly patients with DLBCL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>three years</time_frame>
    <description>All patients will be evaluated for the toxicity during the treatment. Toxicity is graded according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC v3.0).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>Three years after the completion of rituximab augmentation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Lymphoma, Large B-cell, Diffuse</condition>
  <arm_group>
    <arm_group_label>rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>A dose of 375mg/m2 rituximab will be administered intravenously on day 1 of first to fourth R-CHOP chemotherapy and on day 1, 8, 15, 22 of each augmentation chemotherapy.</description>
    <arm_group_label>rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed CD20 positive DLBCL

          2. Age ≥ 70

          3. Ann Arbor stage II, III and IV

          4. No prior chemotherapy or radiotherapy for DLBCL

          5. Performance status (Eastern Cooperative Oncology Group) ≤ 2

          6. At least one or more bidimensionally measurable lesion(s)

               -  ≥ 2 cm by conventional computerized tomography (CT)

               -  ≥ 1 cm by spiral CT

               -  skin lesion (photographs should be taken) ≥ 2 cm

               -  measurable lesion by physical examination ≥ 2 cm

          7. Cardiac ejection fraction ≥ 50% as measured by echocardiogram without clinically
             significant abnormalities

          8. Adequate renal function: serum creatinine level &lt; 2 mg/dL (177 μmol/L)

          9. Adequate liver functions:

         10. Adequate bone marrow functions:

             hemoglobin ≥ 9 g/dL absolute neutrophil count ≥ 1,500/μL and platelet count ≥
             75,000/μL, unless abnormalities are due to bone marrow involvement by lymphoma

         11. Life expectancy more than 6 months

         12. Informed consent

        Exclusion Criteria:

          1. Other subtypes of non-Hodgkin's lymphoma

          2. Patients who transformed follicular lymphoma or other indolent lymphoma

          3. Primary Central Nervous System (CNS) DLBCL

          4. CNS involvement by lymphoma or any evidence of spinal cord compression.

          5. Patients with a known history of human immunodeficiency virus (HIV) seropositivity or
             hepatitis C virus (+).

          6. Any other malignancies within the past 5 years except curatively treated non-melanoma
             skin cancer or in situ carcinoma of cervix uteri

          7. Pregnant or lactating women, women of childbearing potential not employing adequate
             contraception

          8. Other serious illness or medical conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Deok-Hwan Yang, M.D. and Ph.D.</last_name>
    <phone>82-61-379-7636</phone>
    <email>drydh1685@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Je-Jung Lee, M.D. and Ph.D.</last_name>
    <phone>82-61-3797638</phone>
    <email>drjejung@chonnam.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hosptial</name>
      <address>
        <city>Jeollanam-do</city>
        <zip>519-809</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deok-Hwan Yang, M.D. and Ph.D.</last_name>
      <phone>82-61-3797636</phone>
      <email>drydh1685@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>So-Young Lee, Nurse</last_name>
      <phone>82-61-3768090</phone>
      <email>kaosin@naver.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2010</study_first_submitted>
  <study_first_submitted_qc>August 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2010</study_first_posted>
  <last_update_submitted>September 21, 2011</last_update_submitted>
  <last_update_submitted_qc>September 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chonnam National University Hospital</investigator_affiliation>
    <investigator_full_name>Deok-Hwan Yang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>diffuse large B-cell lymphoma</keyword>
  <keyword>elderly patients</keyword>
  <keyword>rituximab augmentation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

